Vesugen (Lys-Glu-Asp)

Source-reported examples · not treatment recommendations

Amount

0.5–2 mg per day

Frequency

Once daily

Cycle / observation period

8–12 weeks; source also mentions 16 weeks

Route / research model

Subcutaneous

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• Vesugen is the short peptide Lys-Glu-Asp, abbreviated KED. A primary study examined vascular endothelial-cell proliferation and modeled a possible DNA interaction. A separate small human report provides limited clinical observations that require careful interpretation. Neither source establishes a general promise of improved circulation or slower aging. ^{[1] [2]}
• The 2014 study reported increased Ki-67-associated proliferative signals with Vesugen and another peptide in cultures involving young and old animal tissues and vascular endothelial cells. It also used molecular docking to propose interaction with a region of the MKI67 promoter. The modeling component is not direct proof that the proposed interaction causes the cellular response. ^[1]
• The 2015 Pinealon/Vesugen report contains inconsistent participant totals and describes both favorable interpretations and prooxidant/CD34-marker findings. Its accessible abstract provides insufficient control and allocation detail for a strong clinical conclusion. ^[2]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 16 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. Original endothelial study
2. human report
3. Bull Exp Biol Med (2016)Further reading · Listed in reference bibliography.
4. Molecules (2021)Further reading · Listed in reference bibliography.
5. Adv Gerontol (2016)Further reading · Listed in reference bibliography.
6. Bull Exp Biol Med (2021)Further reading · Listed in reference bibliography.
7. Bull Exp Biol Med (2017)Further reading · Listed in reference bibliography.
8. DailyMedRegulatory / product information · Listed in reference bibliography.
9. PMC (2024)Further reading · Listed in reference bibliography.
10. MedlinePlusGeneral guidance · Listed in reference bibliography.
11. NCBI BookshelfFurther reading · Listed in reference bibliography.
12. Int J Mol Sci (2022)Further reading · Listed in reference bibliography.
13. Pharmaceuticals (2021)Further reading · Listed in reference bibliography.
14. CDCGeneral guidance · Listed in reference bibliography.
15. Biogerontology (2010)Further reading · Listed in reference bibliography.
16. Stem Cell Rev Rep (2020)Further reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.